BNTX icon

BioNTech

108.78 USD
-2.05
1.85%
At close Mar 7, 4:00 PM EST
After hours
108.50
-0.28
0.26%
1 day
-1.85%
5 days
-3.83%
1 month
-7.51%
3 months
-9.97%
6 months
8.21%
Year to date
-5.65%
1 year
19.42%
5 years
224.91%
10 years
663.90%
 

About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Employees: 6,133

0
Funds holding %
of 7,359 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

39% more call options, than puts

Call options by funds: $373M | Put options by funds: $269M

27% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 49

10% more capital invested

Capital invested by funds: $5.25B [Q3] → $5.78B (+$535M) [Q4]

2.71% more ownership

Funds ownership: 18.63% [Q3] → 21.34% (+2.71%) [Q4]

1% more funds holding

Funds holding: 294 [Q3] → 297 (+3) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]

2% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 85

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$170
56%
upside
Avg. target
$171
57%
upside
High target
$172
58%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Truist Securities
Asthika Goonewardene
32% 1-year accuracy
8 / 25 met price target
58%upside
$172
Buy
Initiated
10 Jan 2025
Wells Fargo
Mohit Bansal
63% 1-year accuracy
17 / 27 met price target
56%upside
$170
Overweight
Initiated
11 Dec 2024

Financial journalist opinion

Based on 7 articles about BNTX published over the past 30 days

Neutral
Benzinga
16 hours ago
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
BioNTech SE BNTX will release its fourth-quarter financial results before the opening bell on Monday, March 10.
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Negative
Reuters
2 days ago
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
Negative
Reuters
3 days ago
U.S. FDA places clinical hold on BioNTech's malaria vaccine study
BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an early-to-mid stage trial of its malaria vaccine.
U.S. FDA places clinical hold on BioNTech's malaria vaccine study
Negative
Forbes
1 week ago
FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.
FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled
Positive
Zacks Investment Research
1 week ago
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
Neutral
GlobeNewsWire
1 week ago
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
Positive
Zacks Investment Research
3 weeks ago
What Makes BioNTech (BNTX) a New Buy Stock
BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes BioNTech (BNTX) a New Buy Stock
Negative
Reuters
1 month ago
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel.
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Negative
CNBC
1 month ago
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Neutral
GlobeNewsWire
1 month ago
BioNTech Completes Acquisition of Biotheus
MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates.
BioNTech Completes Acquisition of Biotheus
Charts implemented using Lightweight Charts™